These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15073413)

  • 1. Absorption of the biomimetic chromium cation triaqua-mu3-oxo-mu-hexapropionatotrichromium(III) in rats.
    Clodfelder BJ; Chang C; Vincent JB
    Biol Trace Elem Res; 2004 May; 98(2):159-69. PubMed ID: 15073413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromium-containing biomimetic cation triaqua-mu3-oxo-mu-hexapropionatotrichromium(III) inhibits colorectal tumor formation in rats.
    Pickering A; Chang C; Vincent JB
    J Inorg Biochem; 2004 Aug; 98(8):1303-6. PubMed ID: 15271505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biomimetic [Cr(3)O(O(2)CCH(2)CH(3))(6)(H(2)O)(3)](+ )decreases plasma insulin, cholesterol, and triglycerides in healthy and type II diabetic rats but not type I diabetic rats.
    Sun Y; Clodfelder BJ; Shute AA; Irvin T; Vincent JB
    J Biol Inorg Chem; 2002 Sep; 7(7-8):852-62. PubMed ID: 12203022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations.
    Bennett R; Adams B; French A; Neggers Y; Vincent JB
    Biol Trace Elem Res; 2006 Oct; 113(1):53-66. PubMed ID: 17114815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromium oligopeptide activates insulin receptor tyrosine kinase activity.
    Davis CM; Vincent JB
    Biochemistry; 1997 Apr; 36(15):4382-5. PubMed ID: 9109644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of the biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ increases insulin sensitivity and improves blood plasma variables in healthy and type 2 diabetic rats.
    Clodfelder BJ; Gullick BM; Lukaski HC; Neggers Y; Vincent JB
    J Biol Inorg Chem; 2005 Mar; 10(2):119-30. PubMed ID: 15625608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the potential for developmental toxicity of prenatal exposure to two dietary chromium supplements, chromium picolinate and [Cr3O(O2CCH2CH3)(6(H2O)3]+, in mice.
    Bailey MM; Sturdivant J; Jernigan PL; Townsend MB; Bushman J; Ankareddi I; Rasco JF; Hood RD; Vincent JB
    Birth Defects Res B Dev Reprod Toxicol; 2008 Feb; 83(1):27-31. PubMed ID: 18076115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ decreases plasma cholesterol and triglycerides in rats: towards chromium-containing therapeutics.
    Sun Y; Mallya K; Ramirez J; Vincent JB
    J Biol Inorg Chem; 1999 Dec; 4(6):838-45. PubMed ID: 10631616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary chromium loss associated with diabetes is offset by increases in absorption.
    Rhodes NR; McAdory D; Love S; Di Bona KR; Chen Y; Ansorge K; Hira J; Kern N; Kent J; Lara P; Rasco JF; Vincent JB
    J Inorg Biochem; 2010 Jul; 104(7):790-7. PubMed ID: 20417571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fate of the biomimetic cation triaqua-mu-oxohexapropionatotrichromium(III) in rats.
    Shute AA; Vincent JB
    J Inorg Biochem; 2002 Apr; 89(3-4):272-8. PubMed ID: 12062132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the insulin-sensitive transport of chromium in healthy and model diabetic rats.
    Clodfelder BJ; Upchurch RG; Vincent JB
    J Inorg Biochem; 2004 Mar; 98(3):522-33. PubMed ID: 14987854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
    Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of chromium(III)-supplements in rats and humans.
    Laschinsky N; Kottwitz K; Freund B; Dresow B; Fischer R; Nielsen P
    Biometals; 2012 Oct; 25(5):1051-60. PubMed ID: 22814636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of High Dietary Doses of Chromium(III) Complex with Propionic Acid on Nutritional and Selected Blood Indices in Healthy Female Rats.
    Staniek H; Krejpcio Z; Wieczorek D
    Biol Trace Elem Res; 2016 May; 171(1):192-200. PubMed ID: 26432449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats.
    Wu Y; Ouyang JP; Zhou YF; Wu K; Zhao DH; Wen CY
    Sheng Li Xue Bao; 2004 Aug; 56(4):539-49. PubMed ID: 15322693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the nutritional biochemistry of trivalent chromium.
    Vincent JB
    Proc Nutr Soc; 2004 Feb; 63(1):41-7. PubMed ID: 15070438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B.
    Wu Y; Ou-Yang JP; Wu K; Wang Y; Zhou YF; Wen CY
    Acta Pharmacol Sin; 2005 Mar; 26(3):345-52. PubMed ID: 15715932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, excretion and retention of 51Cr from labelled Cr-(III)-picolinate in rats.
    Kottwitz K; Laschinsky N; Fischer R; Nielsen P
    Biometals; 2009 Apr; 22(2):289-95. PubMed ID: 18923913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypolipidemic activity of 18beta-glycyrrhetinic acid on streptozotocin-induced diabetic rats.
    Kalaiarasi P; Kaviarasan K; Pugalendi KV
    Eur J Pharmacol; 2009 Jun; 612(1-3):93-7. PubMed ID: 19361497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl.
    Cromwell WC; Otvos JD
    Am J Cardiol; 2006 Dec; 98(12):1599-602. PubMed ID: 17145217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.